{"id":"W1970476748","doi":"10.1056/nejmoa050736","title":"Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1854,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; University of Ottawa; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Erlotinib; Medicine; Lung cancer; Epidermal growth factor receptor; Oncology; Internal medicine; Clinical trial; Erlotinib Hydrochloride; Placebo; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02248944063098263,"score_gpt":0.4079720786852618,"score_spread":0.3854826380542792,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}